US Patent 9,358,240 (Treprostinil Pulmonary Hypertension) Claim Scope, Coverage Boundaries, and US Patent Landscape
Executive summary: US 9,358,240 claims a narrow, device-and-regimen-constrained inhalation method for pulmonary hypertension using a pulsed ultrasonic nebulizer with an opto-acoustical trigger that lets the patient synchronize inhalation to each pulse, delivering a fixed “single event dose” of treprostinil (15 to 90 µg) in 1 to 18 breaths, using a formulation concentration of 200 to 1000 µg/mL. Dependent claims add concentration and dosing-interval and pharmacokinetic timing limits. The enforceable scope in the US is primarily method-of-treatment coverage tied to specific dosing architecture and a specific nebulization control feature.
What does US 9,358,240 claim for treprostinil inhalation in pulmonary hypertension?
Direct answer (claim 1 core): The patent is directed to a method of treating pulmonary hypertension by administering, via inhalation, a single event dose of treprostinil (15 to 90 µg) or a pharmaceutically acceptable salt using a pulsed ultrasonic nebulizer with an opto-acoustical trigger that enables breath-by-breath synchronization to the pulses. Delivery is constrained by both formulation concentration (200 to 1000 µg/mL) and delivered dose architecture (fixed amount per pulse; delivered in 1 to 18 breaths). The claim is not merely “inhaling treprostinil,” it is an inhalation method that requires a specific nebulizer triggering approach and a specific dose delivery pattern.
Claim 1: claim map and literal scope boundaries
1) Indication / patient population
- “treating pulmonary hypertension”
- “administering to a human suffering from pulmonary hypertension”
- This is a method-of-use limitation. Infringement requires treatment of the claimed indication in the US.
2) Active / salt
- “200 to 1000 µg/ml of treprostinil or a pharmaceutically acceptable salt thereof” in the formulation.
- “15 µg to 90 µg of treprostinil or its pharmaceutically acceptable salt” as the single event dose delivered.
Literal implication: A generic “treprostinil inhalation” at the wrong formulation concentration or wrong delivered microgram dose per event is outside literal claim 1.
3) Formulation concentration constraint (200–1000 µg/mL)
- The formulation concentration is fixed by the claim range: 200 to 1000 µg/mL.
Infringement sensitivity: “Loaded solution concentration” matters. A product that administers treprostinil inhalation using a lower or higher concentration can avoid literal coverage even if it achieves similar delivered microgram dosing.
4) Delivery device type and triggering feature (pulsed ultrasonic nebulizer + opto-acoustical trigger)
- “pulsed ultrasonic nebulizer”
- “comprising an opto-acoustical trigger which allows said human to synchronize each breath to each pulse”
- “said aerosolizes a fixed amount of treprostinil … per pulse”
Key scope anchor: The claim requires not only nebulization but a pulse-based ultrasonic system with an opto-acoustical trigger enabling patient synchronization for each breath/pulse.
Device design-around pressure point: If a nebulizer uses a different trigger modality (e.g., purely mechanical, pressure-based, airflow-based without opto-acoustic trigger, or timed automatic pulses not synchronized breath-by-breath), literal infringement becomes difficult.
5) “Single event dose” architecture: fixed delivery in 1–18 breaths
- “single event dose … delivered in 1 to 18 breaths”
- “fixed amount per pulse”
- This ties the method to a regimen structure that maps dose onto a limited number of inhalations.
Practical interpretation: The claim defines a breath-count envelope for dose delivery per “event,” not a continuous nebulization approach.
Claim 1: what is not explicitly claimed
Claim 1 does not explicitly require:
- a specific treprostinil salt identity (only “pharmaceutically acceptable salt”)
- a particular inhalation flow rate or mouthpiece configuration
- a specific inhalation technique beyond synchronization to pulses
- a specific patient lung deposition target (only dose and timing dependencies in dependents)
How do dependent claims narrow US 9,358,240 beyond claim 1?
Claim 2: fixed formulation concentration of 600 µg/mL
- “wherein the formulation comprises 600 µg/ml treprostinil …”
Coverage effect: Claim 2 adds a strict concentration: 600 µg/mL. This is a narrower subset of claim 1.
Claim 3: dosing interval requirement (no repeat for at least 3 hours)
- “single event dose is not repeated for a period of at least 3 hours”
Coverage effect: Requires the regimen schedule constraint. Even if the administration device and dose architecture match, repeated dosing sooner than 3 hours can fall outside claim 3 (but may still infringe claim 1 if claim 1 is asserted and does not require spacing).
Claim 4: peak plasma concentration timing (about 10–15 minutes)
- “produces a peak plasma concentration … about 10–15 minutes after the single event dose”
Coverage effect: This is a pharmacokinetic outcome limitation. It can be used in enforcement where the accused product’s PK profile for pulmonary hypertension patients aligns with the claimed window.
Claim 5 and Claim 6: per-breath fixed minimum delivered amount
- Claim 5: “fixed amount … for each breath … comprises at least 5 µg”
- Claim 6: depends from claim 2 and repeats “at least 5 µg per breath”
Coverage effect: These claims push against designs where the dose is distributed across many breaths with small microgram-per-breath increments. They also complicate defense efforts that argue similar total dose but different per-breath micro-dosing.
Claim 7 and Claim 8: breath-count range (3–18 breaths)
- Claim 7: “single event dose is inhaled in 3–18 breaths”
- Claim 8: depends from claim 6 and repeats “3–18 breaths”
Coverage effect: Narrows claim 1’s “1 to 18” to “3 to 18.” A device or regimen that delivers the single event dose in only 1–2 breaths is outside claim 7/8.
Claim 9: dosing interval repeated not for at least 3 hours
- Depends from claim 6 and repeats claim 3’s spacing requirement.
What is the practical claim coverage boundary: total dose, concentration, breaths, and trigger?
Four-part “literal infringement” checklist for claim 1:
- Indication: pulmonary hypertension treatment of a human.
- Formulation concentration: 200–1000 µg/mL treprostinil (or salt).
- Single event delivered dose: 15–90 µg per event.
- Device and control:
- pulsed ultrasonic nebulizer
- opto-acoustical trigger permitting breath-to-pulse synchronization
- fixed amount aerosolized per pulse
- delivered in 1–18 breaths
Where a competitor can design around most effectively:
- Change the trigger/control architecture so it is not “opto-acoustical” and/or not synchronized “each breath to each pulse.”
- Change formulation concentration out of 200–1000 µg/mL.
- Change delivered microgram dose per event out of 15–90 µg.
- Change breath-count mapping such that dose is not delivered in 1–18 breaths.
- Use a non-single-event continuous regimen or a schedule that avoids the “single event dose” structure (and, for dependent claims, the ≥3 hour spacing).
Is US 9,358,240 likely to cover salt forms and different treprostinil presentations?
Claim language is salt-inclusive. It covers “treprostinil or a pharmaceutically acceptable salt thereof.” That means enforcement does not hinge on a single chemical salt identity, provided the accused product uses treprostinil (or acceptable salt) and meets the concentration and dosing constraints.
But device regimen constraints still dominate: Even with the correct drug substance, absence of the specific nebulizer triggering feature and breath-by-breath pulse synchronization reduces literal risk.
What do the PK and dosing-interval dependent limitations mean for enforcement strategy?
Dependent claims 3 and 4 create outcome and regimen constraints that can be used in different proof settings:
- Claim 3 (≥3 hours between single event doses): focuses on the dosing schedule used in actual use or prescribing instructions.
- Claim 4 (peak plasma at ~10–15 minutes): can be supported by clinical data. For enforcement, this can be powerful when the accused product’s label and PK data align with the claimed window.
Risk note for challengers: If a competitor’s regimen is similar but their dosing interval and PK profile diverge, they may reduce the likelihood of proving dependent claim infringement even if claim 1 is arguably approached on device and dosing architecture.
How does this claim set compare to typical inhaled treprostinil approaches in pulmonary arterial hypertension?
Most treprostinil inhalation strategies in the US landscape rely on:
- continuous or intermittently pulsed nebulization without patient-controlled breath-to-pulse synchronization as a critical claim element, or
- delivery systems where the patient does not synchronize each breath to each pulse via an opto-acoustic triggering mechanism, or
- device-agnostic method-of-use language that focuses on dose and indication.
US 9,358,240 is distinguishable because it ties coverage to:
- a particular ultrasonic pulsed delivery architecture
- an opto-acoustical trigger allowing breath synchronization
- dose “per pulse” fixedness and breath-count mapping.
That structure is likely intended to separate patent coverage from more generic “inhaled treprostinil for pulmonary hypertension” methods.
What US patent landscape issues affect freedom to operate around US 9,358,240?
Landscape framing (US): In real-world FTO assessments, US 9,358,240 should be evaluated alongside:
- device patents covering nebulizers (especially ultrasonic pulsed systems and breath-sensing triggers),
- formulation patents covering treprostinil concentration, stability, and aerosolization behavior,
- method-of-use patents covering pulmonary hypertension indications, dosing regimens, and PK targets,
- manufacturing process patents for drug-in-nebulizer or solution prep.
However: this analysis cannot enumerate or map other US patents, expiry dates, assignees, Orange Book status, or litigation without the patent’s bibliographic record, family members, and cited documents.
Key takeaways
- US 9,358,240 claim 1 is method-of-treatment plus device-and-dosing architecture: inhaled treprostinil for pulmonary hypertension delivered via a pulsed ultrasonic nebulizer with an opto-acoustical trigger enabling breath-by-breath synchronization to pulses.
- Coverage is constrained by loaded formulation concentration (200–1000 µg/mL) and delivered single-event dose (15–90 µg), delivered in 1–18 breaths.
- Dependent claims further narrow to 600 µg/mL (claim 2), ≥3 hour dosing interval (claim 3), PK peak at ~10–15 minutes (claim 4), ≥5 µg per breath (claims 5 and 6), and 3–18 breaths (claims 7 and 8), with spacing repeated in claim 9.
- The most direct design-around lever in US litigation is typically the trigger/control feature (opto-acoustical trigger and breath synchronization) and the concentration/breath mapping rather than the mere fact of inhaled treprostinil.
FAQs
1) What elements of US 9,358,240 are required for claim 1 infringement?
Pulmonary hypertension treatment in a human, treprostinil formulation at 200–1000 µg/mL, a single-event dose of 15–90 µg, delivered by a pulsed ultrasonic nebulizer with an opto-acoustical trigger that synchronizes each breath to each pulse, delivering a fixed amount per pulse across 1–18 breaths.
2) Does US 9,358,240 cover treprostinil salts as well as treprostinil?
Yes. Claim 1 and the dependents use “treprostinil or a pharmaceutically acceptable salt thereof,” so salt identity is not the limiting feature.
3) Can a competitor avoid claim 2 while still implicating claim 1?
Yes. Claim 2 is the subset with 600 µg/mL formulation. A regimen using a concentration within 200–1000 µg/mL but not equal to 600 µg/mL could still fall under claim 1 but not claim 2.
4) What dosing changes affect dependent claim 3 (≥3 hours)?
Any regimen that repeats the “single event dose” more frequently than 3 hours can reduce or avoid dependent claim 3 infringement. Claim 1 itself does not require the ≥3 hour spacing.
5) What is the significance of the breath-count limits (1–18 vs 3–18)?
Claim 1 covers a single event dose delivered in 1–18 breaths. Dependent claims 7 and 8 require 3–18 breaths, so delivering the full single-event dose in only 1–2 breaths avoids those dependents while remaining potentially within claim 1.
